Description: Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Home Page: septerna.com
250 East Grand Avenue
South San Francisco,
CA
94080
United States
Phone:
650 338 3533
Officers
| Name | Title |
|---|---|
| Dr. Jeffrey T. Finer M.D., Ph.D. | Co-Founder, CEO, President & Director |
| Ms. Elizabeth P. Bhatt M.B.A., M.S. | Chief Operating Officer |
| Ms. Samira Shaikhly | Chief People Officer |
| Dr. Daniel Long DPHIL | Senior Vice President of Drug Discovery |
| Mr. Uwe Klein Ph.D. | Senior Vice President of Biological Sciences |
| Dr. Robert J. Lefkowitz M.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Dr. Arthur Christopoulos BPHARM, Ph.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Dr. Patrick Sexton Ph.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Ms. Ran Xiao C.F.A., M.B.A. | Interim CFO and VP of Finance & Business Operations |
| Mr. Richard Hansen Ph.D. | Vice President of Technology |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-10-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 68 |